AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17050867 — intervention group
Group type: COMPARATOR
Intervention: irinotecan 100 mg/m2 and gemcitabine 1,000 mg/m2 without celecoxib
Number of subjects: 133
Study 14639148 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 70
Study 14639148 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 70
Study 14639148 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine and Ropivacaine
Number of subjects: 70
Study 10958273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary and intravenous nicorandil during PTCA (group N)
Number of subjects: 48
Study 10958273 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 48
Study 8720537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 mg/day metformin
Number of subjects: 75
Study 8720537 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg/day metformin
Number of subjects: 75
Study 8720537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 1448711 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (10 million U by subcutaneous injection, 3 times a week for 16 weeks)
Number of subjects: 20
Study 1448711 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 1448711 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b
Number of subjects: 20
Study 4052301 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg kg‐1
Number of subjects: 7
Study 4052301 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.04 ml kg‐1
Number of subjects: 7
Study 31662153 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell therapy (various types including neural, haematopoietic, mesenchymal, differentiated embryonic stem cells, and induced pluripotent stem cells)
Number of subjects: 200
Study 30350517 — intervention group
Group type: EXPERIMENTAL
Intervention: Group discussion among malaria control staff
Number of subjects: 24
Study 26313291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 161
Study 26313291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine
Number of subjects: 161
Study 26313291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 161
Study 25011604 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic mixing (9 months) using third- or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems during consecutive antibiotic courses.
Number of subjects: 8
Study 25011604 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic cycling (9 months) using third- or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems during consecutive 6-week periods.
Number of subjects: 8
Study 22189669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense resistance exercise
Number of subjects: 10
Study 22189669 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 10
Study 20923715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile van intervention
Number of subjects: 110432
Study 20923715 — intervention group
Group type: COMPARATOR
Intervention: Door-to-door intervention
Number of subjects: 110432
Study 20923715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions
Number of subjects: 110432
Study 18022845 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state free-precession (SSFP) MRI
Number of subjects: 375
Study 18022845 — intervention group
Group type: COMPARATOR
Intervention: Full MRI
Number of subjects: 375
Study 18022845 — intervention group
Group type: EXPERIMENTAL
Intervention: SSFP
Number of subjects: 375
Study 15864217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 53
Study 15864217 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 53
Study 12834663 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Chamber Intraocular Lens (PC IOL)
Number of subjects: 438
Study 12834663 — intervention group
Group type: COMPARATOR
Intervention: Anterior Chamber Intraocular Lens (AC IOL)
Number of subjects: 438
Study 12834663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 438
Study 11720758 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP regimen (2 or 4 cycles) in perioperative setting
Number of subjects: 100
Study 11720758 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 100
Study 11720758 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 100
Study 11720758 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (cisplatin based)
Number of subjects: 100
Study 9167759 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (lomustine 80 mg/m2 day 1; carboplatin 80 mg/m2 days 1, 8, 15, 22; vinorelbine 20 mg/m2 days 1, 8, 15, 22; L-leucovorin 250 mg/m2 days 1, 8, 15, 22; fluorouracil 500 mg/m2 days 1, 8, 15, 22; cycles repeated every 6 weeks)
Number of subjects: 28
Study 8271805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes (substance type)
Number of subjects: 579
Study 8271805 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (substance type)
Number of subjects: 579
Study 8271805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (substance type)
Number of subjects: 579
Study 8271805 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (recovery method)
Number of subjects: 579
Study 8271805 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-change (recovery method)
Number of subjects: 579
Study 3515931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 11
Study 3515931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3515931 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Volunteers
Number of subjects: 11
Study 3515931 — intervention group
Group type: COMPARATOR
Intervention: Patients
Number of subjects: 11
Study 31175909 — intervention group
Group type: EXPERIMENTAL
Intervention: brodalumab 210 mg every 2 weeks
Number of subjects: 0
Study 31175909 — intervention group
Group type: EXPERIMENTAL
Intervention: brodalumab 210 mg every 2 weeks after ustekinumab
Number of subjects: 0
Study 31175909 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous brodalumab 210 mg every 2 weeks
Number of subjects: 0
Study 31175909 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety through 120 weeks
Number of subjects: 0
Study 29050498 — intervention group
Group type: EXPERIMENTAL
Intervention: Program A (no analgesics or acute migraine-medication)
Number of subjects: 72
Study 29050498 — intervention group
Group type: COMPARATOR
Intervention: Program B (acute medication restricted to two days/week)
Number of subjects: 72
Study 27440499 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable Video Media (PVM)
Number of subjects: 88
Study 27440499 — intervention group
Group type: COMPARATOR
Intervention: Standard Verbal Communication (SVC)
Number of subjects: 88
Study 24796042 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-strong stimulation group
Number of subjects: 120
Study 24796042 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 120
Study 24796042 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture + medication group
Number of subjects: 120
Study 24796042 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (triple-strong stimulation, acupuncture, acupuncture + medication)
Number of subjects: 120
Study 23081745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol (100/10 or 250/10 μg b.i.d.)
Number of subjects: 202
Study 23081745 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/salmeterol (100/50 or 250/50 μg b.i.d.)
Number of subjects: 202
Study 19752761 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy and atorvastatin (80 mg/day)
Number of subjects: 64
Study 19752761 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 64
Study 19752761 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (atorvastatin)
Number of subjects: 64
Study 19752761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19263677 — intervention group
Group type: EXPERIMENTAL
Intervention: Participative education (PE)
Number of subjects: 202
Study 19263677 — intervention group
Group type: COMPARATOR
Intervention: Traditional education (TE)
Number of subjects: 202
Study 15914987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel application
Number of subjects: 773
Study 12941201 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy
Number of subjects: 556
Study 12941201 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 556
Study 16463756 — intervention group
Group type: EXPERIMENTAL
Intervention: support/work-planning intervention
Number of subjects: 151
Study 16463756 — intervention group
Group type: COMPARATOR
Intervention: standard prenatal curriculum group
Number of subjects: 151
Study 10188889 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg beta-carotene
Number of subjects: 141
Study 10188889 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C
Number of subjects: 141
Study 10188889 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene
Number of subjects: 141
Study 10188889 — intervention group
Group type: EXPERIMENTAL
Intervention: vitamin C
Number of subjects: 141
Study 10188889 — intervention group
Group type: EXPERIMENTAL
Intervention: both vitamins
Number of subjects: 141
Study 7591527 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with long-chain polyunsaturated fatty acids (LCP-F)
Number of subjects: 32
Study 7591527 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 32
Study 7591527 — intervention group
Group type: COMPARATOR
Intervention: Formula without LCP
Number of subjects: 32
Study 2301715 — intervention group
Group type: COMPARATOR
Intervention: amikacin/metronidazole/placebo (Group 1, 56 patients)
Number of subjects: 156
Study 2301715 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin/clindamycin/placebo (Group 2, 57 patients)
Number of subjects: 156
Study 2301715 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin/clindamycin/ampicillin (Group 3, 43 patients)
Number of subjects: 156
Study 2301715 — intervention group
Group type: COMPARATOR
Intervention: amikacin/metronidazole/placebo (Group 1, 13 patients post-exclusion)
Number of subjects: 156
Study 2301715 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin/clindamycin/placebo (Group 2, 45 patients post-exclusion)
Number of subjects: 156
Study 2301715 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful treatment outcomes (106 evaluable patients)
Number of subjects: 156
Study 7447772 — intervention group
Group type: EXPERIMENTAL
Intervention: Retaining the lenses
Number of subjects: 50
Study 7447772 — intervention group
Group type: COMPARATOR
Intervention: Lensectomy
Number of subjects: 50
Study 6150724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 10
Study 6150724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29367324 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Health Choices (IHC) Key Concepts
Number of subjects: 0
Study 29894608 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 68
Study 29894608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 68
Study 29894608 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 68
Study 25518180 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosed plaque visualization
Number of subjects: 122
Study 25518180 — intervention group
Group type: COMPARATOR
Intervention: No disclosed plaque visualization (Control)
Number of subjects: 122
Study 22211824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 15
Study 22211824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20195905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Number of subjects: 4092
Study 18190651 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L PEG + Asc
Number of subjects: 308
Study 18190651 — intervention group
Group type: COMPARATOR
Intervention: 4 L PEG + E
Number of subjects: 308
Study 18190651 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + Asc
Number of subjects: 308
Study 18190651 — intervention group
Group type: COMPARATOR
Intervention: PEG + E
Number of subjects: 308
Study 18190651 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + Asc and PEG + E
Number of subjects: 308
Study 16175842 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-supported intervention
Number of subjects: 0
Study 16175842 — intervention group
Group type: COMPARATOR
Intervention: Clinician-delivered intervention
Number of subjects: 0
Study 12637904 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-point expander
Number of subjects: 30
Study 12637904 — intervention group
Group type: COMPARATOR
Intervention: 4-point expander
Number of subjects: 30
Study 10671603 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume rendering with transition zone reconstructed separately from the wall
Number of subjects: 27
Study 10671603 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface rendering with transition zone attenuation equal to wall attenuation
Number of subjects: 27
Study 10671603 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface rendering with transition zone attenuation equal to air attenuation
Number of subjects: 27
Study 10671603 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface rendering with transition zone attenuation halfway between air and wall
Number of subjects: 27
Study 8836612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg
Number of subjects: 11
Study 8836612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 120 mg
Number of subjects: 11
Study 8836612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 240 mg
Number of subjects: 11
Study 8836612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1344880 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone suppositories or oral dehydroprogesterone
Number of subjects: 0
Study 1344880 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 3830804 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week chemotherapy regimen associated with whole abdominal radiotherapy
Number of subjects: 82
Study 3830804 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for 3 years
Number of subjects: 82
Study 3830804 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone for 3 years (27 stage IIID and 36 stage IV patients)
Number of subjects: 82
Study 3830804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, prednisone for low grade lymphomas (16 patients)
Number of subjects: 82
Study 3830804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, adriamycin, prednisone for intermediate (56 patients) and high grade (10 patients) lymphomas
Number of subjects: 82
Study 29866212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Antipsychotic treatment (specifics not provided)
Number of subjects: 1136
Study 30140963 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 G vitrectomy plus encircling band (group E1)
Number of subjects: 163
Study 30140963 — intervention group
Group type: COMPARATOR
Intervention: 20 G vitrectomy without any buckle (group C)
Number of subjects: 163
Study 27560704 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sleep (EXT; time in bed: 2100‐0700 h)
Number of subjects: 14
Study 27560704 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (HAB; time in bed: 2230‐0700 h)
Number of subjects: 14
Study 27560704 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of sleep deprivation
Number of subjects: 14
Study 25436225 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoliosis-specific exercise treatment
Number of subjects: 144
Study 25436225 — intervention group
Group type: COMPARATOR
Intervention: Observation regime (Control)
Number of subjects: 144
Study 25453004 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and Suxamethonium (PS)
Number of subjects: 88
Study 25453004 — intervention group
Group type: COMPARATOR
Intervention: Propofol and Lidocaine (PL)
Number of subjects: 88
Study 20170514 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of PEG‐IFN‐alpha-2a (180 ug/week) and ribavirin (800‐1200 mg/day)
Number of subjects: 210
Study 20170514 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of PEG‐IFN‐alpha-2a (180 ug/week) and ribavirin (800‐1200 mg/day)
Number of subjects: 210
Study 20170514 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of PEG‐IFN‐alpha-2a and ribavirin (for patients without rapid virological response)
Number of subjects: 210
Study 18325883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 2295
Study 18325883 — intervention group
Group type: COMPARATOR
Intervention: Non-ultrasound-guided embryo transfer
Number of subjects: 2295
Study 15884127 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin
Number of subjects: 50
Study 15884127 — intervention group
Group type: COMPARATOR
Intervention: Control (200 mL of 5% dextrose water)
Number of subjects: 50
Study 12882432 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompting intervention (weekly telephone or mail-delivered cues)
Number of subjects: 190
Study 12882432 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention (3-encounter motivational sessions)
Number of subjects: 190
Study 10673189 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 microg twice daily
Number of subjects: 15
Study 10673189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10673189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (400 ppb for 2 hours)
Number of subjects: 15
Study 9119568 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention study
Number of subjects: 1785
Study 1503061 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation
Number of subjects: 0
Study 1503061 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented children
Number of subjects: 0
Study 6662157 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol hydrochloride 400‐700 mg once daily (mean 612 mg/day)
Number of subjects: 14
Study 30462939 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus R0011 and L. helveticus R0052) at a dose of 4.0×10^9 CFUs twice daily for 5 days
Number of subjects: 886
Study 30462939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 886
Study 30462939 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 886
Study 28317328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.i.d.
Number of subjects: 0
Study 28317328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg b.i.d.
Number of subjects: 0
Study 28317328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg b.i.d.
Number of subjects: 0
Study 28317328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg b.i.d.
Number of subjects: 0
Study 28317328 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight influence on dosage
Number of subjects: 0
Study 26131783 — intervention group
Group type: COMPARATOR
Intervention: Simulators
Number of subjects: 20
Study 26131783 — intervention group
Group type: EXPERIMENTAL
Intervention: Live tissue
Number of subjects: 20
Study 23968383 — intervention group
Group type: EXPERIMENTAL
Intervention: No prophylaxis during surgical procedures
Number of subjects: 331
Study 20385300 — intervention group
Group type: EXPERIMENTAL
Intervention: Short loop group (SLG; n = 110)
Number of subjects: 218
Study 20385300 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (CG; n = 108)
Number of subjects: 218
Study 17996212 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levofloxacin (0.5%) four times on the day before surgery + Povidone-iodine (PVI) irrigation
Number of subjects: 140
Study 17996212 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine (PVI) irrigation alone
Number of subjects: 140
Study 16855194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with parental support group
Number of subjects: 15
Study 16855194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention‐alone group
Number of subjects: 15
Study 16855194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 12632137 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.5% bupivacaine and 5 mg/ml epinephrine
Number of subjects: 50
Study 12632137 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 50
Study 11195900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy with irradiation and heating
Number of subjects: 35
Study 11195900 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound therapy without irradiation or heating (placebo group)
Number of subjects: 35
Study 9028977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 30
Study 9028977 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapleural intercostal nerve block with intermittent low-dose bupivacaine
Number of subjects: 30
Study 9028977 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 30
Study 1504638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent nicotine (15 mu/kg) via nasal spray
Number of subjects: 42
Study 1504638 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 42
Study 1504638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1504638 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 42
Study 1504638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine or smoking
Number of subjects: 42
Study 6408940 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 51
Study 6408940 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheniramine
Number of subjects: 51